Choline kinase inhibitors as a novel approach for antiproliferative drug design

Oncogene

Volumn 15, Issue 19, 1997, Pages 2289-2301

  Hernández Alcoceba, Rubén ^a   Saniger, Luisa ^a   Campos, Joaquín ^b   Núñez, M Carmen ^b   Khaless, Fouad ^b   Gallo, Miguel Angel ^b   Espinosa, Antonio ^b   Lacal, Juan Carlos ^a  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

Antiproliferative drugs; Choline kinase; fos; Growth factors; Hemicholinium 3; Oncogenes; Phosphorylcholine; ras; src

Indexed keywords

ANTINEOPLASTIC AGENT; CHOLINE KINASE; ENZYME INHIBITOR;

ARTICLE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL TRANSFORMATION; DRUG ACTIVITY; DRUG DESIGN; ONCOGENE RAS; PRIORITY JOURNAL;

EID: 0030681263     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1201414     Document Type: Article

References (35)

1. Bar Sagi D and Feramisco JR. (1986). Science, 233, 1061-1068.
2. Bhakoo KK, Williams SR, Florian CL, Land H and Noble MD. (1996). Cancer Res., 56, 4630-4635.
3. Campos Rosa J, Galanakis D, Ganellin CR and Dunn PM. (1996). J. Med. Chem., 39, 4247-4254.
4. Cannon JG, Sahin MF, Long JP, Flynn JR and Bhetnagar RK. (1990). J. Med. Chem., 33, 577-579.
5. Cannon JG. (1994). Med. Res. Rev., 14, 505-531.
6. Carnero A, Cuadrado A, del Peso L and Lacal JC. (1994a). Oncogene, 9, 1387-1395.
7. Carnero A, Dolfi F and Lacal JC. (1994b). J. Cell. Biochem., 54, 478-486.
8. Carnero A and Lacal JC. (1995). Mol. Cell. Biol., 15, 1094-1101.
9. Cuadrado A, Carnero A, Dolfi F, Jiménez B and Lacal JC. (1993). Oncogene, 8, 2959-2968.
10. De Vita VT , Hellman S and Rosenberg SA. (1993). Cancer, Principles and Practice of Oncology, 4th edition. JB Lippincott Com: Philadelphia, USA.
11. Dent P and Sturgill TW. (1994). Proc. Natl. Acad. Sci. USA, 91, 9544-9548.
12. Gillies RJ, Didier N and Denton M. (1986). Anal. Biochem., 159, 109-113.
13. Guyenet P, Lefresne P, Rossier J, Beaujouan JC and Glowinski J. (1973). Mol. Pharmacol., 9, 630-639.
14. Hamza M, Lloveras J, Ribbea G, Soula G and Douste-Blazy L. (1983). Biochem. Pharmacol., 32, 1893-1897.
15. Jiménez B, del Peso L, Montaner S, Esteve P and Lacal JC. (1995). J. Cell. Biochem., 57, 141-149.
16. Kerr DJ and Workman P. (1994). New molecular targets for cancer chemotherapy. CRC Press: Boca Raton, Florida, USA.
17. Lacal JC, Moscat J and Aaronson SA. (1987). Nature, 330, 269-271.
18. Lacal JC. (1990). Mol. Cell. Biol., 10, 333-340.
19. Lacal JC and Carnero A. (1994). Oncology Reports, 1, 677-693.
20. Macara I. (1989). Mol. Cell. Biol., 10, 325-328.
21. MacDonald JS, Haller DG and Mayer RJ. (1995). Manual of Oncologic Therapeutics, 3rd edition. JB Lippincott Com: Philadelphia, USA.
22. Moodie SA, Willumsen BM, Weber MJ and Wolfman A. (1993). Science, 260, 1658-1661.
23. Pelech SL and Vance DE. (1984). Biochem. Biophys. Acta, 779, 217-251.
24. del Peso L, Lucas L, Esteve P and Lacal JC. (1997). Biochem. J., 322, 519-528.
25. Polak RL, Molenaar PC and van Gelder M. (1977). J. Neurochem., 29, 477-485.
26. Ratnam S and Kent C. (1995). Arch. Biochem. Biophys., 323, 313-322.
27. Rodríguez Viciana P, Warne PH, Dhand R, Vanhaesebroech B, Gout I, Fry MJ, Waterfield MD and Downward J. (1994). Nature, 370, 527-532.
28. Ronen SM, Rushkin E and Degani H. (1991). Biochem. Biophys. Acta, 1095, 5-16.
29. Ronen SM, Rushkin E and Degani H. (1992). Biochem. Biophys. Acta, 1138, 203-212.
30. Teegarden D, Taparowsky EJ and Kent C. (1990). J. Biol. Chem., 265, 16638-16643.
31. Tucek S. (1985). J. Neurochem., 44, 12-24.
32. Vojtek AB, Hollenberg MS and Cooper JA. (1993). Cell, 74, 204-214.
33. Warne PH, Rodríguez-Viciana P and Downward J. (1993). Nature, 364, 352-355.
34. Zhang X-F, Settleman J, Kyriakis JM, Takeuchi-Suzuki E, Elledges J, Marshall MS, Bruder JT, Rapp UR and Avruch J. (1993). Nature, 364, 308-313.
35. Zlatkine P, Moll G, Biais A, Loiseau A and Grimellec CL. (1993). Biochem. Biophys. Acta, 1153, 237-242.